Niklas Worm Andersson News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Niklas worm andersson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Niklas Worm Andersson Today - Breaking & Trending Today

Thiazide Diuretics May Promote Hyponatremia

The risk for hyponatremia was higher with thiazide drugs compared with nonthiazide drugs in older adults and patients with comorbidities. ....

Niklas Worm Andersson , Statens Serum Institut , Medscape Medical , Internal Medicine , Data Reinforce Need , Noel Deep , Aspirus Langlade Hospital , Hyponatremia Hyponatraemia , Adverse Effects , Side Effects , Elder Care , Geriatric Medicine , Older Adults , Senior Citizens , Patient Safety , Calcium Channel Blockers , Drug Reaction , Private Practice , Renin Angiotensin System , Enin Angiotensin Aldosterone System Ras Renin ,

Treatment initiation with thiazide diuretics increases hyponatremia risk, researchers find

Treatment initiation with thiazide diuretics increases hyponatremia risk, researchers find
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Worm Andersson , Statens Serum Institut , Niklas Worm Andersson , Cumulative Incidence , Thiazide Induced Hyponatremia , Internal Medicine ,

LDL-Lowering Tied to Lower First CVD Events in Patients 70+

People 70 years of age and older taking LDL cholesterol-lowering therapy for primary prevention have the same reduction in major vascular events as their younger counterparts, new research confirms. ....

Safiu Khan , Novo Nordisk , Vascular Center , Department Of Epidemiology Research , Journal Of The American College Cardiology , Houston Methodist Debakey Heart , Niklas Worm Andersson , Epidemiology Research , Statens Serum Institut , American College , Tine Lovs , Ipid Management , Low Ldl Cholesterol , Ow Low Density Lipoprotein Cholesterol , Atherosclerotic Heart Disease , Therosclerotic Cardiovascular Disease , Oronary Heart Disease , Schemic Heart Disease , Erebrovascular Accident , Va Cerebrovascular Accident , Body Mass Index Bmi , Cardiovascular Disease , Vd Cardi ,

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Objective To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19.

Design Nationwide cohort analyses, using target trial emulation.

Setting Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023.

Participants People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster).

Main outcome measures The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people.

Results A total of 1 634 199 people receiving bivalent BA.4-5 fourth dose booster and 1 042 124 ....

United Kingdom , North Carolina , United States , Nicklas Pihlstr , Ulrike Baum , Hinta Meijerink , Emilia Myrup Thiesson , Rickard Ljung , Jostein Starrfelt , Spikevax Moderna , Eero Poukka , Anders Hviid , European Medicines Agency , Finnish Medical Foundation , Sanofi Aventis , Niklas Worm Andersson , Myrup Thiesson , Conclusion Vaccination , European Medicines , Open Access , Creative Commons Attribution Non Commercial ,

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

Objective To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events.

Design Nationwide cohort study.

Setting Denmark.

Participants 2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses during the study period, 1 January 2021 to 10 December 2022.

Main outcome measures The main outcome measure was rates of hospital visits for 27 different adverse events in a 28 day main risk period after vaccination with a bivalent omicron adapted mRNA booster vaccine as a fourth dose compared with reference period rates from day 29 after the third or fourth vaccine dose and onward.

Results 1 740 417 adults (mean age 67.8 years, standard deviation 10.7 years) received a bivalent mRNA vaccine as a fourth dose. Fourth dose vaccination with a bivalent mRNA vaccine was not associated with a statistically significant increased rate of any of the 27 adverse ....

Anders Hviid , Emilia Myrup Thiesson , Drug Administration , Centers For Disease , Us Centers For Disease , Danish Ministry Of Health , Danish Health , Niklas Worm Andersson , Myrup Thiesson , Disease Control , Vaccine Adverse Event Reporting System , Safety Datalink , Statens Serum Institut , Danish Ministry , Open Access , Creative Commons Attribution Non Commercial ,